Rx License-Rx

TAB-4991

TYROSINASE Gene Therapy for Oculocutaneous Albinism type 1A

Summary: The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A. Description of Technology: Oculocutaneous albinism (OCA) is a genetically heterogeneous congenital disorder characterized by decreased or absent pigmentation in the hair, skin and eyes. The absence of pigmentation is caused by insufficient melanin production – an important pigment providing normal black color to important eye tissues such as the iris and retinal pigment epithelium. Lack of melanin in the eye results in abnormal development and impaired vision. Individuals diagnosed with OCA1, the most common type if albinism worldwide (1:40,000 people), is caused by mutations in the TYROSINASE (TYR) gene. OCA1A patients suffer complete loss of melanin caused by inactivity of the TYROSINASE enzyme. Currently, there is no treatment. Scientist at the National Eye...

Intelligence Memo

Owner: National Institutes of Health

Core category: Therapeutics

Therapeutic area: Rare Disease

Indication: Rare/Neglected Diseases

Modality: Cell/Gene Therapy

Focus tags: Rare Disease, Ophthalmology, Infectious Disease

Technology tags: Cell/Gene Therapy, Biologic, Drug Delivery, Biomanufacturing

Mechanism:

Development stage: Preclinical

Patent status: Expired; Administratively Closed; Pending

Availability: Available for license

Plain-English Licensing Breakdown

This is a license opportunity for a therapeutic asset or drug-enabling technology in Rare Disease. In plain English, the buyer would be licensing science that could become a treatment program, usually after more validation. The current package appears to be preclinical and is associated with National Institutes of Health. The practical first use case is Rare/Neglected Diseases. Public description: Summary: The National Eye Institute seeks research co-development partners and/or licensees for an adeno-associated viral gene therapy for Oculocutaneous Albinism type 1A. Description of Technology: Oculocutaneous albinism (OCA) is a.

What is exciting

Already past pure discovery: Preclinical validation gives a buyer something concrete to reproduce, optimize, or package into an IND-enabling plan.

The eye can create faster proof: Local delivery, imaging endpoints, and smaller patient groups can make ophthalmology assets easier to de-risk than broad systemic programs.

Delivery can refresh known biology: A better route, depot, local exposure profile, or targeted formulation can create new IP and reduce systemic risk around existing mechanisms.

Hot modality with strategic appetite: Cell and gene therapy buyers care when there is a crisp antigen, genetic subgroup, potency assay, or manufacturing shortcut.

Negatives / diligence concerns

Translation still unproven: Animal or lab data may not predict human performance; tox, PK/PD, CMC, and indication selection still need diligence.

Manufacturing can dominate the budget: Potency assays, vector or cell process reproducibility, release testing, and COGS can become bigger risks than the biology.

Exposure advantage must be real: Delivery stories fail when biodistribution, local tolerability, stability, or payload compatibility does not beat simpler alternatives.

Risk Flags

  • Human validation and clinical path require diligence.
  • Patent scope and remaining exclusivity need review with counsel.
  • Inventor readiness and licensing terms are not yet verified.

Strategic Pharma Attractiveness

Large pharma would care if this becomes more than an interesting university-originated technology: it needs a crisp Rare Disease wedge, a measurable value inflection, and a diligence package that makes the first deal feel like an option on upside rather than a blind research bet.

Most logical pharma targets Regeneron — Retina commercial leadership and appetite for durability/delivery improvements. Roche — Ophthalmology franchise plus biologics and delivery infrastructure. Astellas / Iveric — Retina specialization and complement/orphan-eye adjacency.

Development Strategy to Increase PoS

First indication: Rare/Neglected Diseases

Study design: Ocular tolerability, local PK, and small image-based proof-of-mechanism study.

Key experiments Validate the AI-optimized pivot: Reframe as a localized orphan-retina or front-of-eye precision program Run independent replication of the core claim with pre-specified success criteria Generate a partner-facing risk register that separates solved, testable, and unresolved risks

Final Recommendation

Proceed: Worth a short exclusive option if diligence confirms IP scope and inventor data quality. The most investable version is: Reframe as a localized orphan-retina or front-of-eye precision program

Best next experiment: Run the smallest independent study that validates: Switch from systemic exposure to intravitreal, topical, or depot delivery and use OCT/ERG/imaging biomarkers as early go/no-go endpoints.

Best licensing timing: Begin BD conversations after the next validation package; pursue a license, option, or asset sale once the first value inflection is visible.